Jefferies maintains Roche at buy

Roche Holdings Corp. was maintained by Jefferies International Ltd. analyst Nick Turner at a buy rating with a raised price target of CHF 220. Jefferies said the company has top-tier sales growth driven by high-margin drugs. Several key registration filings and regulatory reviews should give the stock the spotlight. Shares of the Basel, Switzerland, pharmaceutical company were up CHF 2.60, or 1.27%, at CHF 206.90 on volume of 2,865,537 shares versus the three-month running average of 2,145,810 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.